# US 2021/0292349 A1 · Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0292349 A1
- Document ID: US20210292349A1
- Status: Published application
- Kind: A1
- Application number: 17/257,917
- Filed: 2019-07-05
- Published: 2021-09-23
- Earliest claimed: 2018-07-06
- Assignees: Kancera AB
- Applicants: Kancera AB
- Inventors: Jan VÅGBERG; Styrbjörn BYSTRÖM; Elisabeth OLSSON; Mattias JÖNSSON
- Web page: https://patentgrep.com/patent/US20210292349A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

## Claims

### Claim 1

A compound of formula I,
wherein
R1 represents aryl or pyridyl, both of which are optionally substituted by one or more groups selected from halo, —CN, —C(O)NR3R4, —S(O)2R5, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, wherein the latter three groups are optionally substituted by one or more F;
R2 represents H or C1-6 alkyl optionally substituted by one or more F;
R3 and R4 each independently represent H or C1-6 alkyl optionally substituted by one of more F;
R5 represents C1-6 alkyl optionally substituted by one or more F;
represents
wherein “” indicates a point of attachment to the rest of the molecule;
Q1 and Q2 each independently represent H or —PO(OR6)(OR7);
Q3 represents H or —CH2OPO(OR6)(OR7); and
Q4 represents —CH2OPO(OR6)(OR7);
wherein R6 and R7 each independently represent H, C1-4 alkyl or C2-4 alkenyl;
wherein at least one of Q1, and Q2, Q3 or Q4 represents —PO(OR6)(OR7) or —CH2OPO(OR6)(OR7);
or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, wherein R1 represents phenyl or pyridyl, both of which are optionally substituted by one or more fluoro, chloro, bromo, —CN, —C(O)NR3R4 or —S(O)2Me group.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein R1 represents phenyl or pyridyl, both of which are optionally substituted by one or more fluoro, chloro or bromo group.

### Claim 4 (depends on 2)

A compound as claimed in claim 2, wherein R1 represents phenyl or 5-chloropyridin-2-yl.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein R2 represents C1-6 alkyl optionally substituted by one or more F.

### Claim 6 (depends on 1)

A compound as claimed in claim 1, wherein R2 represents C1-3 alkyl.

### Claim 7 (depends on 6)

A compound as claimed in claim 6, wherein R2 represents methyl.

### Claim 8 (depends on 1)

A compound as claimed in claim 1, wherein one of Q1 and Q2, Q3 or Q4 represents —PO(OR6)(OR7) or —CH2OPO(OR6)(OR7), and the remainder of Q1, and (if present) Q2 or Q3 represent H.

### Claim 9 (depends on 1)

A compound as claimed in claim 1, wherein
represents

### Claim 10 (depends on 9)

A compound as claimed in claim 9, wherein
represents

### Claim 11 (depends on 9)

A compound as claimed in claim 9, wherein
represents

### Claim 12 (depends on 1)

A compound as claimed in claim 1, wherein Q1 represents —PO(OR6)(OR7).

### Claim 13 (depends on 9)

A compound a claimed in claim 9, wherein Q2 represents —PO(OR6)(OR7).

### Claim 14 (depends on 9)

A compound as claimed in claim 9, wherein Q3 represents —CH2OPO(OR6)(OR7).

### Claim 15 (depends on 1)

A compound as claimed in claim 1, wherein
represents

### Claim 16 (depends on 1)

A compound as claimed in claim 1, wherein the compound is a compound of formula IA,
wherein R1, R2, Q1, Q2 and
are as defined in any one of the preceding claims, or a pharmaceutically-acceptable salt thereof.

### Claim 17 (depends on 1)

A compound as claimed in claim 1, wherein R6 and R7 each independently represent C1-3 alkyl or H.

### Claim 18 (depends on 17)

A compound as claimed in claim 17, wherein R6 and R7 each represent H.

### Claim 19 (depends on 17)

A compound as claimed in claim 17, wherein R6 and R7 each represent methyl or each represent ethyl.

### Claim 20 (depends on 17)

A compound as claimed in claim 17, wherein R6 represents iso-propyl and R7 represents H.

### Claim 21 (depends on 1)

A compound as claimed in claim 1, wherein the pharmaceutically-acceptable salt is a base addition salt.

### Claim 22 (depends on 21)

A compound as claimed in claim 21, wherein the pharmaceutically-acceptable salt is an ammonium salt or an alkali metal salt.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound a defined in claim 1, including pharmaceutically-acceptable salts thereof, in admixture with one or more pharmaceutically-acceptable excipient.

### Claim 24 (depends on 23)

A pharmaceutical composition as claimed in claim 23, wherein the pharmaceutical composition further comprises water and less than 20% (w/w) of solubilising excipients.

### Claim 25 (depends on 24)

A pharmaceutical composition as claimed in claim 24, wherein the pharmaceutical composition is in the form of an aqueous solution.

### Claim 26 (depends on 23)

A pharmaceutical composition as claimed in claim 23, wherein the composition is in the form of a powder.

### Claim 27 (depends on 1, 23, 24, 25, 26)

A compound as defined in claim 1, including pharmaceutically-acceptable salts thereof, or a pharmaceutical composition as defined in any one of claims 23 to 26, for use in medicine.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A method of treating and/or preventing a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 comprising administering to a patient in need thereof, a therapeutically effective amount of a compound as defined in claim 1.

### Claim 30

(canceled)

### Claim 31 (depends on 29)

The method of claim 29, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

### Claim 32 (depends on 29)

The method of claim 29, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from macular degeneration, pulmonary arterial hypertension, asthma, pulmonary fibrosis, atopic dermatitis, pruritus, osteoarthritis, osteoporosis, aplastic anaemia, ankylosing spondylitis, multiple sclerosis, systemic sclerosis, rheumatoid arthritis, atherosclerosis, unstable angina, myocardial infarction, carotid artery diseases, chronic heart failure, inflammatory cardiomyopathy, peripheral artery disease, diabetes, Alzheimer's disease, traumatic brain injury, chronic pain, fibromyalgia, neuropathic pain, chemotherapy-induced pain, intervertebral disc herniation, cancer, liver cirrhosis, IgA nephropathy, renal inflammation, lupus, ischemia reperfusion injury, ischemic acute renal failure, contrast-induced kidney injury, colitis, Crohn's disease, inflammatory bowel disease, pancreatitis human immunodeficiency virus-1 human immunodeficiency virus-associated dementia, stroke, Parkinson's disease, depression, anxiety, schizophrenia and autism spectrum disorders.

### Claim 33 (depends on 29)

The method of claim 29, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from myocardial infarction, arteriosclerosis, multiple sclerosis, rheumatoid arthritis, Crohn's disease, pancreatitis, neuropathic pain chemotherapy-induced pain and cancer.

### Claim 34 (depends on 29)

The method of claim 29, wherein the disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1 is selected from atopic dermatitis, multiple sclerosis, rheumatoid arthritis, atherosclerosis, myocardial infarction, chronic heart failure, inflammatory cardiomyopathy, fibromyalgia, neuropathic pain, chemotherapy-induced pain, B-cell lymphomas, breast cancer, IgA nephropathy, lupus, ischemic acute renal failure and pancreatitis.

### Claim 35 (depends on 1)

A combination product comprising:
(I) a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof; and
(II) one or more other therapeutic agent that is useful in the treatment or prevention of a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1,
wherein each of components (I) and (II) is formulated in admixture, optionally with a pharmaceutically-acceptable excipient, such as a pharmaceutically-acceptable adjuvant diluent or carrier.

### Claim 36 (depends on 23)

A kit-of-parts comprising:
(a) a pharmaceutical composition as defined in claim 23; and
(b) a pharmaceutical composition comprising one or more other therapeutic agent that is useful in the treatment or prevention of a disease or disorder associated with elevated levels of CX3CR1 and/or CX3CL1, formulated in admixture with a pharmaceutically-acceptable excipient,
which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

### Claim 37 (depends on 1)

A process for the preparation of a compound as defined in claim 1, which process comprises:
(a) for compounds wherein Q1 represents —PO(OR6)(OR7), wherein R6 and R7 are as defined in any one of the preceding claims
(i) reacting a compound of formula II
wherein R1 and R2 are as defined in any one of the preceding claims; and
represents
with phosphorus oxychloride in the presence of a suitable solvent and a suitable base; then
(ii) adding water or R6OH/R7OH to the reaction mixture;
(b) for compounds wherein Q2 represents —PO(OR6)(OR7),
reacting a compound of formula III
wherein:
R1 and R2 are as defined in any one of the preceding claims; and
PG1 represents a suitable oxygen protecting group;
in the presence of phosphorus pentachloride, a suitable solvent and, optionally, a suitable base;
(c) for compounds wherein Q3 or Q4 represents —CH2OPO(OR6)(OR7) and at least one of R6 and R7 represents C1-4 alkyl or C2-4 alkenyl,
reacting a compound of formula II
wherein R1 and R2 are as defined herein; and
represents
with a compound of formula IV
wherein R6 and R7 are as defined in any one of the preceding claims with the proviso that at least one of R6 and R7 represents C1-4 alkyl or C2-4 alkenyl and LG1 represents a suitable leaving group;
in the presence of a suitable base and a suitable solvent;
(d) for compounds wherein Q3 or Q4 represents —CH2OPO(OH)2,
(i) reacting a compound of formula II
wherein R1 and R2 are as defined herein; and
represents
with a compound of formula V
wherein R8 and R9 represent C1-6 alkyl and LG2 represents a suitable leaving group;
in the presence of a suitable base and a suitable solvent; and
(ii) reacting the product formed in the presence of a suitable acid and a suitable solvent.
